Thermo Fisher Scientific Q3 GAAP operating income climbs 17% to $2.26 billion
TMO•Thermo Fisher Scientific’s third-quarter 2026 revenue rose 9% year over year to $12.14 billion, while GAAP operating income climbed 17% to $2.26 billion. GAAP diluted earnings per share increased 9% to $4.64.
1. Third-quarter results
Thermo Fisher Scientific reported third-quarter 2026 revenue of $12.14 billion, up 9% year over year, and GAAP operating income of $2.26 billion, up 17%. GAAP diluted earnings per share rose 9% to $4.64. The company also completed its microbiology business divestiture and launched Precure with Mayo Clinic to advance earlier disease detection.
